A Randomized, Open-Label, Single Dose, Four Way Cross-Over Bioavailability Study Comparing Three Modified Release Formulations Of Apixaban Tablets To Apixaban Immediate Release Tablets In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Apixaban (Primary)
- Indications Acute coronary syndromes; Deep vein thrombosis; Pulmonary embolism; Stroke; Thrombosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2009 Status changed from not yet recruiting to active, no longer recruiting as reporte by ClinicalTriasl.gov
- 18 Jun 2009 New trial record